The global Immuno-Oncology market size was valued at USD 44910 million in 2022 and is forecast to a readjusted size of USD 114190 million by 2029 with a CAGR of 14.3% during review period.
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
The industry's leading producers are Bristol-Myers Squibb, Merck & Co and Roche AG, with revenues of 27.89%, 22.10% and 20.85%, respectively, in 2019.
This report is a detailed and comprehensive analysis for global Immuno-Oncology market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Immuno-Oncology market size and forecasts, in consumption value ($ Million), 2018-2029
Global Immuno-Oncology market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Immuno-Oncology market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Immuno-Oncology market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Immuno-Oncology
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Immuno-Oncology market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Hospitals
Drugstores
Others
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Strengths:
- Rapid advancements in immuno-oncology therapies, leading to novel treatment options for cancer patients.
- Strong pipeline of drugs, with major pharmaceutical companies heavily investing in research and development.
Weaknesses:
- High treatment costs limiting accessibility for patients in low-income regions.
- Limited understanding of long-term effects and resistance mechanisms of immunotherapies.
Opportunities:
- Expanding indications for immunotherapies to treat a broader range of cancers.
- Increasing partnerships and collaborations between biotech firms and pharmaceutical companies.
Threats:
- Regulatory hurdles and delays in drug approvals potentially slowing market growth.
- Risk of market saturation with several similar immuno-oncology treatments entering the space.
Political:
- Government funding and policies supporting cancer research are crucial to accelerating immuno-oncology development.
- Increasing regulation on drug pricing and reimbursement could impact market accessibility and profitability.
Economic:
- Rising healthcare costs may limit patient access to expensive immuno-oncology treatments in low-income markets.
- Economic downturns can affect the level of investment in innovative cancer therapies, slowing market growth.
Social:
- Growing awareness of cancer treatment options and patient advocacy can drive demand for immuno-oncology therapies.
- Increased focus on personalized medicine and patient-centered care is shaping the demand for tailored immunotherapies.
Technological:
- Advancements in artificial intelligence and machine learning are improving the efficiency of drug discovery in immuno-oncology.
- Breakthroughs in genetic and molecular profiling are enhancing the ability to identify suitable patients for immunotherapies.
Environmental:
- Sustainability concerns in pharmaceutical manufacturing could influence the production and distribution of immuno-oncology drugs.
- Environmental impact of clinical trials, including waste disposal and energy consumption, could face increased scrutiny.
Legal:
- Intellectual property protection and patent laws will continue to shape competition and innovation in the immuno-oncology market.
- Ongoing litigation regarding patent rights for immuno-oncology drugs may lead to market uncertainty.
Suppliers:
- Pharmaceutical companies, biotech firms, and academic institutions providing cutting-edge research and clinical trial data.
- Manufacturers of biologics and therapeutic agents that produce the raw materials for immuno-oncology treatments.
Inputs:
- Innovative cancer treatment technologies, including immunotherapies and targeted therapies.
- Regulatory guidelines, clinical trial data, and patient health data used for drug development and approval.
Process:
- Research and development of new immuno-oncology treatments, including clinical trials and approval processes.
- Manufacturing and distribution of approved therapies to healthcare providers and hospitals.
Outputs:
- New immuno-oncology drugs and therapies approved for a broader range of cancer types.
- Enhanced survival rates and improved quality of life for cancer patients treated with immunotherapies.
Customers:
- Oncology specialists, healthcare providers, and medical institutions treating cancer patients.
- Patients seeking innovative cancer treatment options and improved outcomes.
Threat of New Entrants:
- High entry barriers due to significant investment in R&D, clinical trials, and regulatory approval processes.
- Established companies with strong patent protections and market presence make it difficult for new players to compete.
Bargaining Power of Suppliers:
- Limited number of suppliers for specialized raw materials and biologics used in immuno-oncology treatments.
- High demand for novel therapies increases the leverage of suppliers, particularly in biologics and advanced technologies.
Bargaining Power of Buyers:
- Healthcare providers and patients have limited bargaining power due to the high cost and specialization of immuno-oncology treatments.
- As the market expands and more treatment options become available, patients and providers may gain some leverage in negotiating prices.
Threat of Substitute Products:
- Traditional cancer treatments, such as chemotherapy and radiation, still remain alternatives to immuno-oncology therapies.
- Development of new, less expensive cancer treatments may reduce the demand for immuno-oncology options.
Industry Rivalry:
- Intense competition among large pharmaceutical companies and biotech firms to innovate and capture market share.
- The presence of multiple players with similar immuno-oncology products may lead to price competition and increased marketing efforts.
Raw Materials and Inputs:
- High-quality biologic materials, such as monoclonal antibodies and cytokines, are critical inputs for immuno-oncology drug development.
- Advanced technologies for genetic sequencing and biomarker identification play a significant role in creating targeted immunotherapies.
Research and Development:
- Significant investment in early-stage R&D, including preclinical studies and clinical trials, is essential for developing new immuno-oncology treatments.
- Collaborative efforts between pharmaceutical companies, academic institutions, and research organizations are driving innovation in the immuno-oncology pipeline.
Regulatory Environment:
- Stringent regulations for drug approval, including clinical trial protocols and FDA/EMA approvals, significantly impact development timelines and market entry.
- Ongoing regulatory developments, such as expedited approval pathways for breakthrough therapies, are helping speed up market introduction.
Supply Chain and Manufacturing:
- Specialized manufacturing facilities are required for the production of biologic drugs, which can be resource-intensive and costly.
- Supply chain disruptions or shortages in key raw materials, such as biologic components or specialized equipment, may affect the timely production of immuno-oncology therapies.
Manufacturing and Production:
- Biopharmaceutical companies focus on scalable production of immuno-oncology drugs, often relying on specialized facilities for biologics manufacturing.
- Ensuring consistent quality and regulatory compliance in production is crucial, as biologic therapies require rigorous controls during manufacturing processes.
Distribution and Logistics:
- Cold chain logistics are essential for the safe transportation and storage of temperature-sensitive immuno-oncology drugs.
- Distribution networks need to be optimized to ensure timely delivery to healthcare providers globally, especially in regions with complex healthcare infrastructure.
Marketing and Sales:
- Strategic partnerships between pharmaceutical companies and healthcare providers are vital for market penetration and adoption of immuno-oncology therapies.
- High-cost barriers in marketing and sales, as well as competition from other immunotherapies, necessitate effective pricing strategies and strong value propositions.
Clinical Trials and Testing:
- Ongoing clinical trials and patient recruitment are central to proving the safety and efficacy of new immuno-oncology therapies, which affects market introduction.
- Real-world evidence from clinical trials is increasingly used to justify treatment efficacy and secure reimbursement from insurance providers.
Healthcare Providers and Hospitals:
- Oncology clinics and hospitals are the primary settings for administering immuno-oncology therapies, with a growing demand for specialized medical staff and facilities.
- Healthcare providers are increasingly incorporating immuno-oncology treatments into standard cancer care protocols, driving adoption and patient referrals.
Patients and End-Users:
- Patient access to immuno-oncology therapies depends on factors such as insurance coverage, affordability, and geographic location.
- Growing patient awareness and advocacy are contributing to increased demand for advanced cancer treatments, especially immuno-oncology options.
Regulatory and Reimbursement Landscape:
- Reimbursement policies and healthcare insurance play a pivotal role in determining patient access to immuno-oncology therapies, with varying coverage across markets.
- Regulatory approvals for new immuno-oncology drugs and treatment regimens are critical for market expansion and broadening patient access.
Post-Treatment Monitoring and Support:
- Long-term patient monitoring for side effects and efficacy is essential, with healthcare providers offering ongoing support through follow-up visits and cancer care programs.
- The rising need for personalized care and patient support services enhances the overall treatment experience and improves patient outcomes.
Chapter 1, to describe Immuno-Oncology product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Immuno-Oncology, with revenue, gross margin and global market share of Immuno-Oncology from 2018 to 2023.
Chapter 3, the Immuno-Oncology competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Immuno-Oncology market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Immuno-Oncology.
Chapter 13, to describe Immuno-Oncology research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Immuno-Oncology
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Immuno-Oncology by Type
1.3.1 Overview: Global Immuno-Oncology Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Immuno-Oncology Consumption Value Market Share by Type in 2022
1.3.3 Immune Checkpoint Inhibitors
1.3.4 Cytokine-Based Immunotherapy
1.3.5 Cancer Vaccines
1.3.6 CAR-T Cell Therapy
1.3.7 Others
1.4 Global Immuno-Oncology Market by Application
1.4.1 Overview: Global Immuno-Oncology Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals
1.4.3 Drugstores
1.4.4 Others
1.5 Global Immuno-Oncology Market Size & Forecast
1.6 Global Immuno-Oncology Market Size and Forecast by Region
1.6.1 Global Immuno-Oncology Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Immuno-Oncology Market Size by Region, (2018-2029)
1.6.3 North America Immuno-Oncology Market Size and Prospect (2018-2029)
1.6.4 Europe Immuno-Oncology Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Immuno-Oncology Market Size and Prospect (2018-2029)
1.6.6 South America Immuno-Oncology Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Immuno-Oncology Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Bristol-Myers Squibb
2.1.1 Bristol-Myers Squibb Details
2.1.2 Bristol-Myers Squibb Major Business
2.1.3 Bristol-Myers Squibb Immuno-Oncology Product and Solutions
2.1.4 Bristol-Myers Squibb Immuno-Oncology Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.2 Merck & Co., Inc.
2.2.1 Merck & Co., Inc. Details
2.2.2 Merck & Co., Inc. Major Business
2.2.3 Merck & Co., Inc. Immuno-Oncology Product and Solutions
2.2.4 Merck & Co., Inc. Immuno-Oncology Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Merck & Co., Inc. Recent Developments and Future Plans
2.3 Roche AG
2.3.1 Roche AG Details
2.3.2 Roche AG Major Business
2.3.3 Roche AG Immuno-Oncology Product and Solutions
2.3.4 Roche AG Immuno-Oncology Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Roche AG Recent Developments and Future Plans
2.4 AstraZeneca, Plc
2.4.1 AstraZeneca, Plc Details
2.4.2 AstraZeneca, Plc Major Business
2.4.3 AstraZeneca, Plc Immuno-Oncology Product and Solutions
2.4.4 AstraZeneca, Plc Immuno-Oncology Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 AstraZeneca, Plc Recent Developments and Future Plans
2.5 Sanofi S.A.
2.5.1 Sanofi S.A. Details
2.5.2 Sanofi S.A. Major Business
2.5.3 Sanofi S.A. Immuno-Oncology Product and Solutions
2.5.4 Sanofi S.A. Immuno-Oncology Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Sanofi S.A. Recent Developments and Future Plans
2.6 Dendreon Pharmaceuticals
2.6.1 Dendreon Pharmaceuticals Details
2.6.2 Dendreon Pharmaceuticals Major Business
2.6.3 Dendreon Pharmaceuticals Immuno-Oncology Product and Solutions
2.6.4 Dendreon Pharmaceuticals Immuno-Oncology Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Dendreon Pharmaceuticals Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Immuno-Oncology Product and Solutions
2.7.4 Novartis Immuno-Oncology Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novartis Recent Developments and Future Plans
2.8 Gilead Sciences Inc.
2.8.1 Gilead Sciences Inc. Details
2.8.2 Gilead Sciences Inc. Major Business
2.8.3 Gilead Sciences Inc. Immuno-Oncology Product and Solutions
2.8.4 Gilead Sciences Inc. Immuno-Oncology Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Gilead Sciences Inc. Recent Developments and Future Plans
2.9 Merck KGaA
2.9.1 Merck KGaA Details
2.9.2 Merck KGaA Major Business
2.9.3 Merck KGaA Immuno-Oncology Product and Solutions
2.9.4 Merck KGaA Immuno-Oncology Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Merck KGaA Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Immuno-Oncology Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Immuno-Oncology by Company Revenue
3.2.2 Top 3 Immuno-Oncology Players Market Share in 2022
3.2.3 Top 6 Immuno-Oncology Players Market Share in 2022
3.3 Immuno-Oncology Market: Overall Company Footprint Analysis
3.3.1 Immuno-Oncology Market: Region Footprint
3.3.2 Immuno-Oncology Market: Company Product Type Footprint
3.3.3 Immuno-Oncology Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Immuno-Oncology Consumption Value and Market Share by Type (2018-2023)
4.2 Global Immuno-Oncology Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Immuno-Oncology Consumption Value Market Share by Application (2018-2023)
5.2 Global Immuno-Oncology Market Forecast by Application (2024-2029)
6 North America
6.1 North America Immuno-Oncology Consumption Value by Type (2018-2029)
6.2 North America Immuno-Oncology Consumption Value by Application (2018-2029)
6.3 North America Immuno-Oncology Market Size by Country
6.3.1 North America Immuno-Oncology Consumption Value by Country (2018-2029)
6.3.2 United States Immuno-Oncology Market Size and Forecast (2018-2029)
6.3.3 Canada Immuno-Oncology Market Size and Forecast (2018-2029)
6.3.4 Mexico Immuno-Oncology Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Immuno-Oncology Consumption Value by Type (2018-2029)
7.2 Europe Immuno-Oncology Consumption Value by Application (2018-2029)
7.3 Europe Immuno-Oncology Market Size by Country
7.3.1 Europe Immuno-Oncology Consumption Value by Country (2018-2029)
7.3.2 Germany Immuno-Oncology Market Size and Forecast (2018-2029)
7.3.3 France Immuno-Oncology Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Immuno-Oncology Market Size and Forecast (2018-2029)
7.3.5 Russia Immuno-Oncology Market Size and Forecast (2018-2029)
7.3.6 Italy Immuno-Oncology Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Immuno-Oncology Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Immuno-Oncology Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Immuno-Oncology Market Size by Region
8.3.1 Asia-Pacific Immuno-Oncology Consumption Value by Region (2018-2029)
8.3.2 China Immuno-Oncology Market Size and Forecast (2018-2029)
8.3.3 Japan Immuno-Oncology Market Size and Forecast (2018-2029)
8.3.4 South Korea Immuno-Oncology Market Size and Forecast (2018-2029)
8.3.5 India Immuno-Oncology Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Immuno-Oncology Market Size and Forecast (2018-2029)
8.3.7 Australia Immuno-Oncology Market Size and Forecast (2018-2029)
9 South America
9.1 South America Immuno-Oncology Consumption Value by Type (2018-2029)
9.2 South America Immuno-Oncology Consumption Value by Application (2018-2029)
9.3 South America Immuno-Oncology Market Size by Country
9.3.1 South America Immuno-Oncology Consumption Value by Country (2018-2029)
9.3.2 Brazil Immuno-Oncology Market Size and Forecast (2018-2029)
9.3.3 Argentina Immuno-Oncology Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Immuno-Oncology Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Immuno-Oncology Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Immuno-Oncology Market Size by Country
10.3.1 Middle East & Africa Immuno-Oncology Consumption Value by Country (2018-2029)
10.3.2 Turkey Immuno-Oncology Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Immuno-Oncology Market Size and Forecast (2018-2029)
10.3.4 UAE Immuno-Oncology Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Immuno-Oncology Market Drivers
11.2 Immuno-Oncology Market Restraints
11.3 Immuno-Oncology Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Immuno-Oncology Industry Chain
12.2 Immuno-Oncology Upstream Analysis
12.3 Immuno-Oncology Midstream Analysis
12.4 Immuno-Oncology Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Immuno-Oncology Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Immuno-Oncology Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Immuno-Oncology Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Immuno-Oncology Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 6. Bristol-Myers Squibb Major Business
Table 7. Bristol-Myers Squibb Immuno-Oncology Product and Solutions
Table 8. Bristol-Myers Squibb Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Bristol-Myers Squibb Recent Developments and Future Plans
Table 10. Merck & Co., Inc. Company Information, Head Office, and Major Competitors
Table 11. Merck & Co., Inc. Major Business
Table 12. Merck & Co., Inc. Immuno-Oncology Product and Solutions
Table 13. Merck & Co., Inc. Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Merck & Co., Inc. Recent Developments and Future Plans
Table 15. Roche AG Company Information, Head Office, and Major Competitors
Table 16. Roche AG Major Business
Table 17. Roche AG Immuno-Oncology Product and Solutions
Table 18. Roche AG Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Roche AG Recent Developments and Future Plans
Table 20. AstraZeneca, Plc Company Information, Head Office, and Major Competitors
Table 21. AstraZeneca, Plc Major Business
Table 22. AstraZeneca, Plc Immuno-Oncology Product and Solutions
Table 23. AstraZeneca, Plc Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. AstraZeneca, Plc Recent Developments and Future Plans
Table 25. Sanofi S.A. Company Information, Head Office, and Major Competitors
Table 26. Sanofi S.A. Major Business
Table 27. Sanofi S.A. Immuno-Oncology Product and Solutions
Table 28. Sanofi S.A. Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Sanofi S.A. Recent Developments and Future Plans
Table 30. Dendreon Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 31. Dendreon Pharmaceuticals Major Business
Table 32. Dendreon Pharmaceuticals Immuno-Oncology Product and Solutions
Table 33. Dendreon Pharmaceuticals Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Dendreon Pharmaceuticals Recent Developments and Future Plans
Table 35. Novartis Company Information, Head Office, and Major Competitors
Table 36. Novartis Major Business
Table 37. Novartis Immuno-Oncology Product and Solutions
Table 38. Novartis Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Novartis Recent Developments and Future Plans
Table 40. Gilead Sciences Inc. Company Information, Head Office, and Major Competitors
Table 41. Gilead Sciences Inc. Major Business
Table 42. Gilead Sciences Inc. Immuno-Oncology Product and Solutions
Table 43. Gilead Sciences Inc. Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Gilead Sciences Inc. Recent Developments and Future Plans
Table 45. Merck KGaA Company Information, Head Office, and Major Competitors
Table 46. Merck KGaA Major Business
Table 47. Merck KGaA Immuno-Oncology Product and Solutions
Table 48. Merck KGaA Immuno-Oncology Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Merck KGaA Recent Developments and Future Plans
Table 50. Global Immuno-Oncology Revenue (USD Million) by Players (2018-2023)
Table 51. Global Immuno-Oncology Revenue Share by Players (2018-2023)
Table 52. Breakdown of Immuno-Oncology by Company Type (Tier 1, Tier 2, and Tier 3)
Table 53. Market Position of Players in Immuno-Oncology, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 54. Head Office of Key Immuno-Oncology Players
Table 55. Immuno-Oncology Market: Company Product Type Footprint
Table 56. Immuno-Oncology Market: Company Product Application Footprint
Table 57. Immuno-Oncology New Market Entrants and Barriers to Market Entry
Table 58. Immuno-Oncology Mergers, Acquisition, Agreements, and Collaborations
Table 59. Global Immuno-Oncology Consumption Value (USD Million) by Type (2018-2023)
Table 60. Global Immuno-Oncology Consumption Value Share by Type (2018-2023)
Table 61. Global Immuno-Oncology Consumption Value Forecast by Type (2024-2029)
Table 62. Global Immuno-Oncology Consumption Value by Application (2018-2023)
Table 63. Global Immuno-Oncology Consumption Value Forecast by Application (2024-2029)
Table 64. North America Immuno-Oncology Consumption Value by Type (2018-2023) & (USD Million)
Table 65. North America Immuno-Oncology Consumption Value by Type (2024-2029) & (USD Million)
Table 66. North America Immuno-Oncology Consumption Value by Application (2018-2023) & (USD Million)
Table 67. North America Immuno-Oncology Consumption Value by Application (2024-2029) & (USD Million)
Table 68. North America Immuno-Oncology Consumption Value by Country (2018-2023) & (USD Million)
Table 69. North America Immuno-Oncology Consumption Value by Country (2024-2029) & (USD Million)
Table 70. Europe Immuno-Oncology Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Europe Immuno-Oncology Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Europe Immuno-Oncology Consumption Value by Application (2018-2023) & (USD Million)
Table 73. Europe Immuno-Oncology Consumption Value by Application (2024-2029) & (USD Million)
Table 74. Europe Immuno-Oncology Consumption Value by Country (2018-2023) & (USD Million)
Table 75. Europe Immuno-Oncology Consumption Value by Country (2024-2029) & (USD Million)
Table 76. Asia-Pacific Immuno-Oncology Consumption Value by Type (2018-2023) & (USD Million)
Table 77. Asia-Pacific Immuno-Oncology Consumption Value by Type (2024-2029) & (USD Million)
Table 78. Asia-Pacific Immuno-Oncology Consumption Value by Application (2018-2023) & (USD Million)
Table 79. Asia-Pacific Immuno-Oncology Consumption Value by Application (2024-2029) & (USD Million)
Table 80. Asia-Pacific Immuno-Oncology Consumption Value by Region (2018-2023) & (USD Million)
Table 81. Asia-Pacific Immuno-Oncology Consumption Value by Region (2024-2029) & (USD Million)
Table 82. South America Immuno-Oncology Consumption Value by Type (2018-2023) & (USD Million)
Table 83. South America Immuno-Oncology Consumption Value by Type (2024-2029) & (USD Million)
Table 84. South America Immuno-Oncology Consumption Value by Application (2018-2023) & (USD Million)
Table 85. South America Immuno-Oncology Consumption Value by Application (2024-2029) & (USD Million)
Table 86. South America Immuno-Oncology Consumption Value by Country (2018-2023) & (USD Million)
Table 87. South America Immuno-Oncology Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Middle East & Africa Immuno-Oncology Consumption Value by Type (2018-2023) & (USD Million)
Table 89. Middle East & Africa Immuno-Oncology Consumption Value by Type (2024-2029) & (USD Million)
Table 90. Middle East & Africa Immuno-Oncology Consumption Value by Application (2018-2023) & (USD Million)
Table 91. Middle East & Africa Immuno-Oncology Consumption Value by Application (2024-2029) & (USD Million)
Table 92. Middle East & Africa Immuno-Oncology Consumption Value by Country (2018-2023) & (USD Million)
Table 93. Middle East & Africa Immuno-Oncology Consumption Value by Country (2024-2029) & (USD Million)
Table 94. Immuno-Oncology Raw Material
Table 95. Key Suppliers of Immuno-Oncology Raw Materials
List of Figures
Figure 1. Immuno-Oncology Picture
Figure 2. Global Immuno-Oncology Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Immuno-Oncology Consumption Value Market Share by Type in 2022
Figure 4. Immune Checkpoint Inhibitors
Figure 5. Cytokine-Based Immunotherapy
Figure 6. Cancer Vaccines
Figure 7. CAR-T Cell Therapy
Figure 8. Others
Figure 9. Global Immuno-Oncology Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 10. Immuno-Oncology Consumption Value Market Share by Application in 2022
Figure 11. Hospitals Picture
Figure 12. Drugstores Picture
Figure 13. Others Picture
Figure 14. Global Immuno-Oncology Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Immuno-Oncology Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Immuno-Oncology Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Immuno-Oncology Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Immuno-Oncology Consumption Value Market Share by Region in 2022
Figure 19. North America Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Immuno-Oncology Revenue Share by Players in 2022
Figure 25. Immuno-Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Immuno-Oncology Market Share in 2022
Figure 27. Global Top 6 Players Immuno-Oncology Market Share in 2022
Figure 28. Global Immuno-Oncology Consumption Value Share by Type (2018-2023)
Figure 29. Global Immuno-Oncology Market Share Forecast by Type (2024-2029)
Figure 30. Global Immuno-Oncology Consumption Value Share by Application (2018-2023)
Figure 31. Global Immuno-Oncology Market Share Forecast by Application (2024-2029)
Figure 32. North America Immuno-Oncology Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Immuno-Oncology Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Immuno-Oncology Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Immuno-Oncology Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Immuno-Oncology Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Immuno-Oncology Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 42. France Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Immuno-Oncology Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Immuno-Oncology Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Immuno-Oncology Consumption Value Market Share by Region (2018-2029)
Figure 49. China Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 52. India Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Immuno-Oncology Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Immuno-Oncology Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Immuno-Oncology Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Immuno-Oncology Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Immuno-Oncology Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Immuno-Oncology Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Immuno-Oncology Consumption Value (2018-2029) & (USD Million)
Figure 66. Immuno-Oncology Market Drivers
Figure 67. Immuno-Oncology Market Restraints
Figure 68. Immuno-Oncology Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Immuno-Oncology in 2022
Figure 71. Manufacturing Process Analysis of Immuno-Oncology
Figure 72. Immuno-Oncology Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
